Allergan PLC (AGN)

Annual Data

Quarterly Data

Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Current Valuation Ratios
Historical Valuation Ratios (Summary)
Price to Earnings (P/E)
Price to Operating Profit (P/OP)
Price to Sales (P/S)
Price to Book Value (P/BV)

Allergan PLC, current price multiples

	Allergan PLC	Abbott Laboratories	AbbVie Inc.	Amgen Inc.	Biogen Inc.	Bristol-Myers Squibb Co.	Celgene Corp.	Eli Lilly & Co.	Gilead Sciences Inc.	Johnson & Johnson	Merck & Co. Inc.	Pfizer Inc.	Regeneron Pharmaceuticals Inc.	Pharmaceuticals & Biotechnology	Health Care
Selected Financial Data
Current share price (P)	$
No. shares of common stock outstanding

Earnings per share (EPS)	$
Operating profit per share	$
Sales per share	$
Book value per share (BVPS)	$
Ratios (Price Multiples)
Price to sales (P/S)
Price to book value (P/BV)

If company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.

Otherwise, if company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.

Allergan PLC, historical price multiples

		Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
	Price to earnings (P/E)
	Price to operating profit (P/OP)
	Price to sales (P/S)
	Price to book value (P/BV)

Ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Allergan PLC's P/E ratio declined from 2015 to 2016 and from 2016 to 2017.
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Allergan PLC's P/S ratio declined from 2015 to 2016 and from 2016 to 2017.
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return.	Allergan PLC's P/BV ratio declined from 2015 to 2016 and from 2016 to 2017.

Allergan PLC, historical P/E calculation, comparison to benchmarks

		Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Net income (loss) attributable to ordinary shareholders (in thousands)
	Earnings per share (EPS)³
	Share price^1, 2
	Ratio
	P/E ratio⁴
	Benchmarks
	P/E Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/E Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/E Ratio, Industry
	Health Care

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Allergan PLC's Annual Report.

2017 Calculations

³ EPS = Net income (loss) attributable to ordinary shareholders ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/E ratio = Share price ÷ EPS
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Allergan PLC's P/E ratio declined from 2015 to 2016 and from 2016 to 2017.

Allergan PLC, historical P/OP calculation, comparison to benchmarks

		Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Operating loss (in thousands)
	Operating profit per share³
	Share price^1, 2
	Ratio
	P/OP ratio⁴
	Benchmarks
	P/OP Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/OP Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/OP Ratio, Industry
	Health Care

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Allergan PLC's Annual Report.

2017 Calculations

³ Operating profit per share = Operating loss ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/OP ratio = Share price ÷ Operating profit per share
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.

Allergan PLC, historical P/S calculation, comparison to benchmarks

		Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Net revenues (in thousands)
	Sales per share³
	Share price^1, 2
	Ratio
	P/S ratio⁴
	Benchmarks
	P/S Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/S Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/S Ratio, Industry
	Health Care

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Allergan PLC's Annual Report.

2017 Calculations

³ Sales per share = Net revenues ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/S ratio = Share price ÷ Sales per share
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Allergan PLC's P/S ratio declined from 2015 to 2016 and from 2016 to 2017.

Allergan PLC, historical P/BV calculation, comparison to benchmarks

		Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Shareholders' equity (in thousands)
	Book value per share (BVPS)³
	Share price^1, 2
	Ratio
	P/BV ratio⁴
	Benchmarks
	P/BV Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/BV Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/BV Ratio, Industry
	Health Care

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Allergan PLC's Annual Report.

2017 Calculations

³ BVPS = Shareholders' equity ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/BV ratio = Share price ÷ BVPS
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return.	Allergan PLC's P/BV ratio declined from 2015 to 2016 and from 2016 to 2017.

	Allergan PLC	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Common Stock Valuation Ratios (Price Multiples)

Current Valuation Ratios

Historical Valuation Ratios (Summary)

Price to Earnings (P/E)

Price to Operating Profit (P/OP)

Price to Sales (P/S)

Price to Book Value (P/BV)